Development and validation of a method for the determination of buprenorphine and norbuprenorphine in breast milk by gas chromatography-mass spectrometry

Biomed Chromatogr. 2012 Mar;26(3):358-62. doi: 10.1002/bmc.1666. Epub 2011 Jul 1.

Abstract

Buprenorphine (BUP) is used for the maintenance of opioid-addicted pregnant women. Because BUP and its main metabolite nor-BUP are excreted into breast milk, a sensitive and specific GC/MS method has been developed, optimized and validated for their determination in breast milk. BUP-d4 was used as internal standard. The sample preparation includes combination of protein precipitation with solid-phase extraction and derivatization (acetylation). The absolute recovery for both analytes was found to be higher than 87.3%. The limits of detection and quantification were 0.07 and 0.20 µg/L, respectively. The calibration curves were linear within the dynamic range 0.20-20.0 µg/L, with a correlation coefficient higher than 0.996. Intra- and inter-day accuracies were ranged from -7.06 to 4.50 and from -5.88 to 7.00%, respectively, while intra- and inter-day precision were less than 5.7 and 6.1%. The analytes were found to be stable in breast milk at 4 °C for one week, at -20 °C for one month, and after three freeze-thaw cycles. The method can be used for the determination of BUP and nor-BUP in breast milk of BUP-maintained mothers, in order to calculate the amount of drug that could pass to the newborn via breast milk and to avoid toxic consequences of breastfeeding.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Buprenorphine / analogs & derivatives*
  • Buprenorphine / analysis*
  • Calibration
  • Gas Chromatography-Mass Spectrometry / methods*
  • Humans
  • Limit of Detection
  • Milk, Human / chemistry*
  • Reference Standards
  • Reproducibility of Results
  • Solid Phase Extraction

Substances

  • Buprenorphine
  • norbuprenorphine